ERJ Podcast May 2025: Efficacy and safety of the activin signalling inhibitor sotatercept

Update: 2025-05-29

Description

As part of the May issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief Editor James Chalmers interviews Associate Editor Marius Hoeper about the efficacy and safety of the activin signalling inhibitor sotatercept in a pooled analysis of PULSAR and STELLAR studies.

Comments

In Channel

ERJ Podcast October 2025: Natural disasters and respiratory health

2025-10-3115:04

Pulmonary Hypertension

2025-10-2321:31

ERJ Podcast September 2025: Neutrophil-derived biomarkers in bronchiectasis

2025-09-2611:20

ERJ Podcast August 2025: Treatment of central sleep apnoea with adaptive servo-ventilation

2025-09-1511:47

Asthma

2025-08-1322:34

ERJ Podcast July 2025: Implementation of European national driving regulations for OSA

2025-07-3112:02

ERJ Podcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma

2025-07-3013:43

ERJ Podcast June 2025: Mechanistic studies in interstitial lung disease

2025-07-0215:13

ERJ Podcast May 2025: Efficacy and safety of the activin signalling inhibitor sotatercept

2025-05-2915:24

ERJ Podcast April 2025: Continuous positive airway pressure and mandibular advancement splints

2025-05-0111:16

ERJ Podcast March 2025: Generalisability of pharmaceutical randomised controlled trial eligibility criteria for progressive pulmonary fibrosis

2025-04-0112:53

ERJ Podcast February 2025: Pre- and post-bronchodilator spirometry in COPD

2025-02-2612:56

ERS Monograph: Lung Transplantation

2025-02-1018:23

ERJ Podcast December 2024: Year in review

2024-12-1717:04

ERJ Podcast November 2024: Fungal disease

2024-11-2514:09

ERS Monograph: COVID-19: An Update

2024-11-1317:48

ERJ Podcast October 2024: World Symposium on Pulmonary Hypertension

2024-11-0217:48

ERS Monograph: The Transition Of Respiratory Care

2024-10-1015:07

ERJ Podcast September 2024: ERS Congress

2024-09-2617:33

ERJ Podcast August 2024: titration of anti-IL-5 biologics in severe asthma

2024-08-2910:23

00:00

ERJ Podcast May 2025: Efficacy and safety of the activin signalling inhibitor sotatercept

#box-pro-ellipsis-176450560465782{-webkit-line-clamp:2;}ERJ Podcast May 2025: Efficacy and safety of the activin signalling inhibitor sotatercept

ERJ Podcast May 2025: Efficacy and safety of the activin signalling inhibitor sotatercept

ERS Publications Podcasts

ERJ Podcast May 2025: Efficacy and safety of the activin signalling inhibitor sotatercept